Culley Brian M — SEC Form 4 filings
SEC reporting owner CIK 1310683. 10 Form 4 filings on record with FilingPulse; latest filed 2026-03-12.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-02-12 to 2026-03-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 3 filings — 65,000 shares, $58,875 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: purchase of 15,000 shares @ $1.62 ($24,375) in Lineage Cell Therapeutics, Inc., filed 2026-03-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | President and CEO, Director | 10 | 3 legs · 65,000 sh · $58,875 | — | 14 |
Form 4 filings — Culley Brian M
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-03-12 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Purchase (P): 15,000 @ $1.62 | EDGAR |
| 2026-03-06 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Grant/award (A): 3,250,000 (derivative) @ $0 | EDGAR |
| 2026-02-13 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Option exercise (M): 31,250 · Tax withholding (F): 12,869 @ $1.80 · Option exercise (M): 31,250 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Grant/award (A): 8,925 · Tax withholding (F): 334 @ $1.68 | EDGAR |
| 2025-03-12 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Grant/award (A): 2,300,000 (derivative) @ $0 | EDGAR |
| 2025-02-12 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Option exercise (M): 31,249 · Tax withholding (F): 12,547 @ $0.65 · Option exercise (M): 31,249 (derivative) @ $0 | EDGAR |
| 2024-11-22 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Purchase (P): 40,000 @ $0.60 | EDGAR |
| 2024-05-28 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Purchase (P): 10,000 @ $1.05 | EDGAR |
| 2024-03-08 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Grant/award (A): 1,900,000 (derivative) @ $0 | EDGAR |
| 2024-02-12 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Option exercise (M): 31,249 · Tax withholding (F): 12,806 @ $1.08 · Option exercise (M): 31,249 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1310683 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →